Direitos para esta edição cedidos à Atena Editora pelos autores. Todo o conteúdo deste livro está licenciado sob uma Licença de Atribuição Creative Commons. Atribuição-Não-Comercial-NãoDerivativos 4.0 Internacional (CC BY-NC-ND 4.0).O conteúdo dos artigos e seus dados em sua forma, correção e confiabilidade são de responsabilidade exclusiva dos autores, inclusive não representam necessariamente a posição oficial da Atena Editora. Permitido o download da obra e o compartilhamento desde que sejam atribuídos créditos aos autores, mas sem a possibilidade de alterá-la de nenhuma forma ou utilizá-la para fins comerciais. Todos os manuscritos foram previamente submetidos à avaliação cega pelos pares, membros do Conselho Editorial desta Editora, tendo sido aprovados para a publicação com base em critérios de neutralidade e imparcialidade acadêmica.A Atena Editora é comprometida em garantir a integridade editorial em todas as etapas do processo de publicação, evitando plágio, dados ou resultados fraudulentos e impedindo que interesses financeiros comprometam os padrões éticos da publicação. Situações suspeitas de má conduta científica serão investigadas sob o mais alto padrão de rigor acadêmico e ético.
The irrational use of drugs today is relevant, so pharmacoeconomics is an analytical tool that links economic factors related to drug use and clinical outcomes. Biological medicines are products derived from genetically modified living cell sources. In this context, the biosimilar drug presents similarity in structure, function, efficacy and safety when compared to the original product. Currently several biosimilars are being developed for the treatment of breast cancer, a fact that directly impacts patient survival. Breast cancer is one of the most common types of cancer, being HER2 positive one of the most aggressive forms of the disease, and its treatment is based on the use of cytotoxic drugs associated with targeted therapy using the monoclonal antibody transtuzumab. There are positive future prospects related to biosimilars with impacts on survival and potential increase of patients with access to innovative treatments. The research aimed to analyze the financial impact of the use of the biosimilar trastuzumab and the increase in the number of patients with access to therapies, through a retrospective documentary cross-sectional study, developed on a representative sample of cost values of the drugs Herceptin and Zedora, for the reference protocol trastuzumab. The results obtained in the descriptive statistics through the analysis of variance were not significant; however, a percentage of savings of 27.89% was obtained for the biosimilar Zedora when compared to Herceptin. Monoclonal antibodies are responsible for 35% of the expenses in oncology. The introduction of biosimilars can contribute to the financial and budgetary sustainability of the health system. Based on the results obtained, it is possible to affirm that for every three patients treated with Herceptin, it is possible to treat four patients using Zedora.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.